IL-13 improves beta-cell survival and protects against IL-1beta-induced beta-cell death. 2016

Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
Department of Genetic Medicine and Development, University of Geneva Medical Center, Geneva, Switzerland. Electronic address: Sabine.RuttiRoch@unil.ch.

OBJECTIVE IL-13 is a cytokine classically produced by anti-inflammatory T-helper-2 lymphocytes; it is decreased in the circulation of type 2 diabetic patients and impacts positively on liver and skeletal muscle. Although IL-13 can exert positive effects on beta-cell lines, its impact and mode of action on primary beta-cell function and survival remain largely unexplored. METHODS Beta-cells were cultured for 48 h in the presence of IL-13 alone or in combination with IL-1β or cytokine cocktail (IL-1β, IFNγ, TNFα). RESULTS IL-13 protected human and rat beta-cells against cytokine induced death. However, IL-13 was unable to protect from IL-1β impaired glucose stimulated insulin secretion and did not influence NFκB nuclear relocalization induced by IL-1β. IL-13 induced phosphorylation of Akt, increased IRS2 protein expression and counteracted the IL-1β induced regulation of several beta-cell stress response genes. CONCLUSIONS The prosurvival effects of IL-13 thus appear to be mediated through IRS2/Akt signaling with NFκB independent regulation of gene expression. In addition to previously documented beneficial effects on insulin target tissues, these data suggest that IL-13 may be useful for treatment of type 2 diabetes by preserving beta-cell mass or slowing its rate of decline.

UI MeSH Term Description Entries

Related Publications

Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
January 2012, Frontiers in bioscience (Elite edition),
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
October 2018, Diabetologia,
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
March 2010, Experimental eye research,
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
September 1990, Journal of immunology (Baltimore, Md. : 1950),
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
May 2011, The Journal of biological chemistry,
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
August 2009, Journal of cellular physiology,
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
April 2022, American journal of respiratory cell and molecular biology,
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
May 2020, Journal of immunology (Baltimore, Md. : 1950),
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
July 2018, Journal of molecular endocrinology,
Sabine Rütti, and Cédric Howald, and Caroline Arous, and Emmanouil Dermitzakis, and Philippe A Halban, and Karim Bouzakri
October 2002, European journal of endocrinology,
Copied contents to your clipboard!